NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

X Master, I agree. I am not concerned about what time of day the milestones occur, or what time of day they are announced. I care about the steady drumbeat of milestones being accomplished and being checked off of my milestone list.

It’s easy to get discouraged and impatient, especially when we have negative voices who are constantly complaining about and disparaging our investment, and NWBio’s senior management team. Some are even nitpicking the time of day each milestone is PR’ed.

Keep in mind that the first 3 milestones on my list have already been accomplished, and the next 2 milestones are imminent, and the last 3 milestones will be reached in “the coming months”:

(1). NWBio releases official DCVax-L top line data.

(2). DCVax-L trial results are published in a top tier peer-reviewed medical journal.

(3). Commercial GMP manufacturing of DCVax-L at the Sawston facility is approved by regulatory authorities in the UK, and throughout the EU.

(4). NWBio patent(s) is/are approved and issued by the USPTO to combine DCVax-L and DCVax Direct with PD-1 and PDL-1 inhibitors to treat solid tumor cancers.

(5). NWBio updates its CDMO agreement with CRL to manufacture DCVax-L for the US and Canada.

(6). NWBio uplists its NWBO shares to a major stock exchange like NASDAQ, NYSE or AMEX.

(7). DCVax-L BLA and MAA are commercially approved for both ndGBM and rGBM patients in the US, Canada, UK, Germany and the rest of the EU.